TrialJournal of hematology & oncology2026

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Nicholas J Short et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.